{
  "docId": "019de076-8fd6-709e-8689-4f849e880c13",
  "docSlug": "045f5237a1062f1479093c113a295dbd",
  "documentTitle": "Alkermes | Investor Conference Presentation Deck | 29 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 29,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The radar chart represents a multi-dimensional optimization framework for drug development.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-8fd6-709e-8689-4f849e880c13/19",
  "deckHref": "/decks/019de076-8fd6-709e-8689-4f849e880c13",
  "deckJsonHref": "/decks/019de076-8fd6-709e-8689-4f849e880c13.json",
  "deckAnchorHref": "/decks/019de076-8fd6-709e-8689-4f849e880c13#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.15,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Radar chart showing five optimization parameters: Oral Bioavailability, Blood Brain Barrier Penetration, Potency, Selectivity, and Pharmacokinetic Properties.",
      "attrs": null,
      "subkind": "radar",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58b41a85-014a-4003-ab3f-9ccdac5e0c4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.35,
        "x": 0.6,
        "y": 0.45
      },
      "kind": "list",
      "text": "Improved wakefulness duration and quality; PK/PD profile that mirrors natural sleep/wake cycle; Cataplexy control; Low therapeutic dose with once-daily oral dosing; Acceptable safety profile with wide therapeutic window",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dafcc431-a745-4afc-a0e4-482d06499e03",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.6,
        "y": 0.27
      },
      "kind": "paragraph",
      "text": "ALKS 2680 Investigational oral orexin 2 receptor agonist for the treatment of narcolepsy designed for:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c23b02b-1ad6-494a-b50b-2d05145258eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.15,
        "y": 0.86
      },
      "kind": "source-note",
      "text": "Potential pharmaceutical profiles are for illustrative purposes only and do not represent any specific development candidate",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "467194f9-9fcd-4d3f-a668-3000cfa887ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "OX2R: Molecular Design Challenge and Optimization Parameters",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14031b45-68a9-4602-810d-b01ee81dbd40",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Big Idea Formula",
      "slug": "big-idea-formula",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "12dc33d4-93b7-468e-aab7-bd5c00d90ef2",
      "evidence": "The slide presents a clear and concise description of the ALKS 2680 program, including its key features and benefits, which is an example of a big idea formula.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "radar-chart",
      "slug": null,
      "matchId": "add6adc7-42fb-419c-a029-a7c83262ddb8",
      "evidence": "Visual representation of multi-dimensional optimization parameters.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 25,
      "from": 16,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "58d89332-74ab-4a79-b132-80fa9e87fcdc",
      "evidence": "The deck presents a problem statement on orexin dysfunction and Alkermes' solution.",
      "position": 0,
      "objective": "What if Alkermes doesn't address orexin dysfunction?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}